PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 227-233 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 235-242 31835640-2 2019 Vortioxetine has a lower affinity to 5-HT1AR and 5-HT7R in rats compared with humans, but several behavior studies have demonstrated its powerful antidepressant-like actions. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 37-44 31835640-8 2019 These demonstrations, the desensitization of 5-HT1AR with the inhibition of 5-HT3R (without 5-HT3R desensitization), at least partially, contribute to the multimodal antidepressant action of vortioxetine in rats. Vortioxetine 191-203 5-hydroxytryptamine receptor 1A Homo sapiens 45-52 30317998-1 2019 BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. Vortioxetine 12-24 5-hydroxytryptamine receptor 1A Homo sapiens 108-114 30317998-2 2019 Series of vortioxetine analogs have been reported as multi antidepressant compounds and they block serotonin transport into the neuronal cells, activate the postsynaptic 5-HT1A receptors and eliminate the low activity of 5-HT3A receptors. Vortioxetine 10-22 5-hydroxytryptamine receptor 1A Homo sapiens 170-176 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 107-112 30457395-7 2019 Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. Vortioxetine 29-41 5-hydroxytryptamine receptor 1A Homo sapiens 108-123 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 494-500 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 411-417 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 5-hydroxytryptamine receptor 1A Homo sapiens 494-500 30194544-29 2019 The maximum dose of vortioxetine is 20 mg daily with improvement in symptoms of depression noted at 2 weeks with a full therapeutic effect observed at 4-6 weeks.Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. Vortioxetine 20-32 5-hydroxytryptamine receptor 1A Homo sapiens 220-226 25418918-4 2014 Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 30-36 29174531-8 2018 This strategy has been incorporated into two new multi-target antidepressant drugs, vilazodone and vortioxetine, which combine 5-HT reuptake inhibition and partial agonism at 5-HT1A receptors. Vortioxetine 99-111 5-hydroxytryptamine receptor 1A Homo sapiens 175-181 26358483-1 2016 Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 93-99 26879252-7 2016 Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist. Vortioxetine 23-35 5-hydroxytryptamine receptor 1A Homo sapiens 225-231 26192901-11 2015 Therefore the newest serotonergic antidepressants including vilazodone and vortioxetine have been designed to possess 5-HT(1A) receptor partial agonist properties. Vortioxetine 75-87 5-hydroxytryptamine receptor 1A Homo sapiens 118-135 27781949-1 2017 BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. Vortioxetine 12-24 5-hydroxytryptamine receptor 1A Homo sapiens 161-176 27781949-1 2017 BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. Vortioxetine 26-29 5-hydroxytryptamine receptor 1A Homo sapiens 161-176 26702943-2 2016 The multimodal-acting antidepressant vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and an inhibitor of the serotonin (5-HT) transporter (SERT) and has pro-cognitive properties. Vortioxetine 37-49 5-hydroxytryptamine receptor 1A Homo sapiens 159-165 26464458-8 2016 Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile. Vortioxetine 62-74 5-hydroxytryptamine receptor 1A Homo sapiens 179-185 25893002-3 2015 Mechanism of Action : Vortioxetine has 5-HT3, 5-HT7 and 5-HT1D antagonists, 5-HT1B partial agonist and a 5-HT1A agonist and serotonin transporter inhibitor property. Vortioxetine 22-34 5-hydroxytryptamine receptor 1A Homo sapiens 105-111 25016186-1 2015 Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 174-189 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 14-24 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 25166025-1 2014 Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine 29-82 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 24676550-6 2014 DATA SYNTHESIS: Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 146-161 25717481-8 2014 Vortioxetine is a novel antidepressant with a unique mechanism of action: it acts through the serotonine reuptake inhibition, but works also as 5HT(1A) agonist, as well as partial agonist of the 5HT(1B) receptor and antagonist of the 5HT(1D), 5HT(3) and 5HT(7) receptors. Vortioxetine 0-12 5-hydroxytryptamine receptor 1A Homo sapiens 144-150 34964415-5 2022 EXPERT OPINION: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT1A receptor, partial agonism of 5-HT1B receptor, and antagonism of 5-HT3, 5-HT1D and 5-HT7 receptors). Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 299-314 24311349-4 2014 In vitro studies indicate that vortioxetine is an inhibitor of the 5-HT transporter and is a 5-HT(1D), 5-HT3 and 5-HT7 receptor antagonist, a 5-HT(1A) receptor agonist and a 5-HT(1B) receptor partial agonist. Vortioxetine 31-43 5-hydroxytryptamine receptor 1A Homo sapiens 142-159 24165478-6 2014 DATA SYNTHESIS: Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. Vortioxetine 16-28 5-hydroxytryptamine receptor 1A Homo sapiens 158-173 23428337-0 2013 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). Vortioxetine 61-73 5-hydroxytryptamine receptor 1A Homo sapiens 10-17 25831967-0 2015 Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). Vortioxetine 51-63 5-hydroxytryptamine receptor 1A Homo sapiens 202-207